IL17A and metabolic dysfunction-associated steatotic liver disease: The progression from MASLD to MASH patients can be monitored by an increased frequency of IL-17+ cells among intrahepatic CD4+ T cells, and noninvasively by a significantly higher Th17/resting Tregs (rTregs; CD4+CD45RA+CD25+) and Th2/rTreg ratio in peripheral blood (16).